H e m a t o lo g y E d u c a t io n - European Hematology Association

49. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance
of von Willebrand factor antigen post-DDAVP in Type 1
von Willebrand disease: is it a potential pathogenic process? J
Thromb Haemost. 2003;1:1714-7.
50. O’Brien LA, James PD, Othman M, Berber E, Cameron C,
Notley CRP, et al. Founder von Willebrand factor haplotype
associated with type 1 von Willebrand disease. Blood. 2003;
102:549-57.
51. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery
RR. The effect of ABO blood group on the diagnosis of von
Willebrand disease. Blood. 1987;69:1691-5.
52. Andrew M, Paes B, Milner R, Johnston M, Mitchell L,
Tollefsen DM, et al. Development of the human coagulation
system in the full-term infant. Blood. 1987;70:165-72.
53. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA.
Variations in coagulation factors in women: effects of age, ethnicity,
menstrual cycle and combined oral coontraceptive.
Thromb Haemost. 1999;82:1456-61.
54. Di Paola J, Federici AB, Mannucci PM, Canciani MT, Kritzik
M, Kunicki TJ, et al. Low Platelet a 2b 1 Levels in Type 1 von
Willebrand Disease Correlate With Impaired Platelet Function
in a High Shear Stress System. Blood. 1999;11:3578-82.
55. Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR,
Mondala TS, et al. An association of candidate gene haplotypes
and bleeding severity in von Willebrand disease (VWD)
type 1 pedigrees. Blood. 2004;104:2359-67.
56. Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F,
Goodeve AC, et al. Identification of a novel P2Y12 variant in
a patient diagnosed with type 1 von Willebrand disease in the
European MCMDM-1VWD study. Blood. 2009;113:4110-3.
London, United Kingdom, June 9-12, 2011
57. Nossent AY, Robben JH, Deen PMT, Vos HL, Rosendaal FR,
Doggen CJM, et al. Functional variation in the arginine vasopressin
2 receptor as a modifier of human plasma von
Willebrand factor levels. J Thromb Haemost. 2010;8:1547-54.
58. Nichols WC, Cooney KA, Mohlke KL, Ballew JD, Yang A,
Bruck ME, et al. von Willebrand disease in the RIIIS/J mouse
is caused by a defect outside of the von Willebrand factor
gene. Blood. 1994;83:3225-31.
59. Mohlke KL, Nichols WC, Westrick RJ, Novak EK, Cooney KA,
Swank RT, et al. A novel modifier gene for plasma von
Willebrand factor level maps to distal mouse chromosome 11.
Proc Natl Acad Sci U S A. 1996;93:15352-7.
60. Onundarson PT, Gudmundsdottir BR, Arnfinnsdottir AV, Kjeld
M, Olafsson O. von Willebrand factor does not vary during
normal menstrual cycle. Thromb Haemost. 2001;85:183-4.
61. Miller CH, Dilley AB, Drews C, Richardson L, Evatt B.
Changes in von Willebrand factor and factor VIII levels during
the menstrual cycle. Thromb Haemost. 2002;87:1082-3.
62. David JL, Gaspard UJ, Gillain D, Raskinet R, Lepot MR.
Hemostasis profile in women taking low-dose oral contraceptives.
Am J Obstet Gynecol. 1990;163:420-3.
63. Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery
in women with von Willebrand’s disease and different von
Willebrand factor mutations. Haematologica. 2009;95:963-9.
64. Ramsahoye BH, Davies SV, Dasani H, Pearson JF. Pregnancy in
von Willebrand’s disease. J Clin Pathol. 1994;47:569-70.
65. Peake IR, Goodeve AC. Genetic testing for von Willebrand
disease: the case for. J Thromb Haemost. 2010;8:13-6.
66. Favaloro EJ. Genetic testing for von Willebrand disease: the
case against. J Thromb Haemost. 2010;8:6-12.
Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1) | 83 |